Last reviewed · How we verify

NCT03517358

Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol

Completed Phase 3 Last updated 31 July 2020
What this trial tests

Phase 3 trial testing Service of care in Hiv in 10 participants. Completed in 1 May 2018.

Timeline
1 January 2018
Primary endpoint
1 May 2018
1 May 2018

Quick facts

Lead sponsorUniversity of California, Davis
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment10
Start date1 January 2018
Primary completion1 May 2018
Estimated completion1 May 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Davis

Who can join

18 and older, any sex, with Hiv. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will look at virologically suppression of patients with HIV who receive pharmacist or case management care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hiv

Currently open trials in the same condition.

Other University of California, Davis trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing